Increases in strychnine-insensiive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis

Biological Psychiatry

Volumn 35, Issue 2, 1994, Pages 84-95

  Ishimaru, Masahiko ^a,b   Kurumaji, Akeo ^a,b   Toru, Michio ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Schizophrenia, glutamate hypothesis, N methyl d aspartate (NMDA) receptor; strychnine insensitive glycine binding site, postmortem brain, radiolabeled receptor assay

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; CYCLOSERINE; GLUTAMIC ACID; GLYCINE; HALOPERIDOL DECANOATE; N METHYL DEXTRO ASPARTIC ACID; SERINE; STRYCHNINE;

ADULT; AGED; ARTICLE; AUTOPSY; BINDING SITE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; BRAIN MAPPING; CEREBRAL CORTEX; CHRONIC DISEASE; FEMALE; GLUTAMATES; GLUTAMIC ACID; GLYCINE; HUMAN; MALE; MIDDLE AGE; RADIOLIGAND ASSAY; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STRYCHNINE; SUPPORT, NON-U.S. GOV'T; UP-REGULATION;

EID: 0028258111     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(94)91197-5     Document Type: Article

References (79)

1. Phencyclidine-induced psychosis
2. Inferior parietal lobule function in spatial perception and visuomotor integration
3. Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-d-aspartate receptor-associated glycine binding site
4. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path
5. Discriminative stimulus properties of PCP mimetics
6. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
7. Excitatory amino acid receptors in the vertebrate central nervous system
8. Glutamate-positive neurons in the somatic sensory cortex of rats and monkeys
9. Glutamate-positive corticocortical neurons in the somatic sensory areas I and II of cats
10. d-Serin antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia
11. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease
12. Two syndromes in schizophrenia and their pathogenesis
13. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
14. Binding to the glycine site of the NMDA receptor complex in brain of patients with Alzheimer's disease
15. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response
16. A “glutamatergic hypothesis” of schizophrenia-rationale for pharmacotherapy with glycine
17. Glutamate: a neurotransmitter in mammalian brain
18. Acidic amino acid binding sites in mammalian neuronal membranes: their characteristics and relationship to synaptic receptors
19. The effects of phencyclidine and N-allynormetazocine on midbrain dopamine neuronal activity
20. 10 dopamine neurons in the rat
21. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls
22. Density and distribution of NMDA receptors in the hippocampus in Alzheimer's disease
23. Alterations in l-glutamate binding in Alzheimer's and Hungtington's disease
24. 3H]glutamate binding
25. The presence of free d-serine in rat brain
26. Evidence for involvement of N-methyl-d-aspartate receptor in tonic inhibitory controle of dopaminergic transmission in rat medial frontal cortex
27. NMDA-associated glycine binding site increases in schizophrenic brains
28. 3H]kainic acid binding sites
29. Negative schizophrenic and the PCP (phencyclidine) model of schizophrenia
30. Recent advances in the phencyclidine model of schizophrenia
31. Glycine potentiates the NMDA response in cultured mouse brain neurons
32. Phencyclidine: behavioral and biochemical evidence supporting a role for dopamine
33. Neuropharmacology of phencyclidine
34. The effect of MK-801 on dopamine metabolism of rat medial frontal cortex
35. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
36. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes
37. The phencyclidine (PCP) analog N-[1(2-benzo[b]thiophenyl)-cyclohexyl] piperidine shares cocaine-like but not other characteristics behavioral effects with PCP, ketamine and MK-801
38. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
39. Localization of higher cognitive and affective functions: the association cortices
40. 3H]Amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: minimal changes in postmortem brains of chronic schizophrenics
41. Molecular diversity of the NMDA receptor channel
42. Protein measurement with the Folin phenol reagent
43. The phencyclidine psychosis
44. Glutamate dysfuncton in Alzheimer's disease: an hypothesis
45. Increase in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens
46. Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs
47. Two classes of N-methyl-d-aspartate recognitionn sites: differential distribution and differential regulation by glycine
48. 3H] glycine recognition site as a modulatory site of the N-methyl-d-aspartate receptor complex
49. 3H]NK-801 binding in Alzheimer's disease
50. 3H]kainic acid binding in the prefrontal cortex in schizophrenia
51. Dysfunction of excitatory amino acidergic systems and schizophrenic disorders
52. 3H]glycine to synaptic membranes in rat brain, treated with Triton X-100
53. Glycine site associated with the NMDA receptor modulates long-term potentiation
54. Role of glycine in the N-methyl-d-aspartate-mediated neuronal cytotoxicity
55. Normal cerebrospinal fluid and brain glutamate levels in schizophrenics do not support the hypothesis of glutamatergic neuronal dysfunction
56. 3H]MK-801 binding in Alzheimer's disease
57. Characterisation of the glycine modulatory site of the N-methyl-d-aspartate receptor-ionophore complex in human brain
58. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study
59. Antipsychotic drugs; direct correlation between clinical potency and presynaptic action on dopamine neurons
60. Evaluation of phencyclidine analogues on the basis of their discriminative stimulus properties in the rat
61. Evidence of glutamatergic deficiency in schizophrenia
62. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics
63. Phencyclidine and ketamine intoxication: a study of four populations of recreational users
64. Phencyclidine and psychotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action
65. Amino acids as neurotransmitters of corticofugal neurones in the rat: a comparison of glutamate and aspartate
66. Increased 3H-MK801 binding in post-mortem brains of chronic schizophrenic patients
67. Phencyclidine increases extracellular dopamine metabolites in rat medial frontal cortex as measured by in vivo dialysis
68. Stereoselective inhibition by d- and l-alanine of phencyclidine-induced locomotor stimulation in the rat
69. Glycine is a coagonist at the NMDA receptor/channel complex
70. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients
71. Antagonism of phencyclidine-induced hyperactivity by glycine in mice
72. MK-801 as an anticonvulsant-preliminary evaluation
73. Plastic response of hippocampal excitatory amino acid receptors to deafferentation and reinnervation
74. Kainate receptors in the rat hippocampus: a distribution and time course of changes in response to unilateral lesions of the entorhinal cortex.
75. Excitatory amino acid transmitters
76. Glycine Therapy of Schizophrenia
77. Phencyclidine-like discriminative stimulus properties of MK-801 in rats
78. Modulation of glutamate receptors: molecular mechanisms and functional implications